Ross Parks, MD
Ophthalmology · Kissimmee, FLNPI 1447251277
Payments from drug & device makers
Across 166 payments — averaging $651.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$103K
- Alcon$1K
- AbbVie$1K
- Aerie Pharmaceuticals, Inc.$431
- Glaukos Corporation$384
- Bausch & Lomb Americas Inc.$311
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,842100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 9 | $102,564 |
| Alcon | 19 | $1,296 |
| AbbVie(2 entities) | 47 | $1,095 |
| Aerie Pharmaceuticals, Inc. | 14 | $431 |
| Glaukos Corporation | 3 | $384 |
| Bausch & Lomb Americas Inc. | 10 | $311 |
| Oyster Point Pharma, Inc. | 12 | $220 |
| Sun Pharmaceutical Industries Inc. | 6 | $220 |
| Apellis Pharmaceuticals, Inc. | 4 | $183 |
| Dompe US, Inc. | 4 | $178 |
| Harrow Eye, LLC | 8 | $177 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $154 |
| Tarsus Pharmaceuticals, Inc. | 2 | $146 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $117 |
| Rxsight Inc | 2 | $112 |
| Kala Pharmaceuticals, Inc. | 1 | $110 |
| Mallinckrodt Hospital Products Inc. | 4 | $106 |
| Sight Sciences, Inc. | 1 | $90 |
| Rayner Intraocular Lenses Limited | 3 | $78 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Astellas Pharma US Inc | 2 | $47 |
| Novartis | 3 | $44 |
| Genentech USA, Inc. | 1 | $25 |
| Akorn, Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Omeros Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$409
- Rocklatan$362
- Rhopressa$362
- CE-marked KXLA system$270
- Clareon PanOptix Pro$146
- Centurion$142
- MIEBO$133
- XIIDRA$133
- Luxor$132
- NGENUITY$132
- AcrySof$130
- LUMIGAN$125
- ALPHAGAN P$125
- DURYSTA$125
- RESTASIS$124
- Syfovre$122
- XDEMVY$122
- ARGOS$117
- TEPEZZA$114
- KXL System$113
How this compares
$108,178 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 238 | $330,028 |
| LumiganBimatoprost | 616 | $318,949 |
| XiidraLifitegrast | 85 | $126,687 |
| RhopressaNetarsudil Mesylate | 151 | $89,989 |
| RocklatanNetarsudil Mesylat/Latanoprost | 134 | $75,023 |
| Alphagan PBrimonidine Tartrate | 109 | $55,459 |
| Cyclosporine | 79 | $51,889 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 180 | $43,469 |
| VyzultaLatanoprostene Bunod | 79 | $35,699 |
| CombiganBrimonidine Tartrate/Timolol | 78 | $35,628 |
| Prednisolone Acetate | 780 | $31,502 |
| Dexamethasone Sodium Phosphate | 498 | $23,066 |
| Brimonidine Tartrate | 805 | $18,477 |
| Ketorolac Tromethamine | 568 | $16,477 |
| Latanoprost | 1,778 | $16,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $1,095 | $740,0641,041 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $431 | $165,012285 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $311 | $162,386164 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm | $154 | $20,31771 claims |
| AlconSimbrinza | $1,296 | $11,75846 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $110 | $11,66815 claims |
| NovartisIlevro | $44 | $8,56119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Kissimmee
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.